acetochlor : A monocarboxylic acid amide that is N-phenylacetamide carrying an ethyl and a methyl group at positions 2 and 6 respectively on the benzene ring while one of the methyl hydrogens as well as the hydrogen attached to the nitrogen atom have been replaced by a chloro and an ethoxymethyl group respectively.
ID Source | ID |
---|---|
PubMed CID | 1988 |
CHEMBL ID | 1517425 |
CHEBI ID | 2394 |
SCHEMBL ID | 21390 |
MeSH ID | M0127677 |
Synonym |
---|
BRD-K16652251-001-02-7 |
acetochlore |
CHEBI:2394 , |
2-chloro-n-(ethoxymethyl)-6'-ethyl-o-acetotoluidide |
2-chloro-2'-methyl-6-ethyl-n-ethoxymethylacetanilide |
2-chloro-n-(ethoxymethyl)-6'-ethylacet-o-toluidide |
2-chloro-n-(ethoxymethyl)-n-(2-ethyl-6-methylphenyl)acetamide |
acetamide, 2-chloro-n-(ethoxymethyl)-n-(2-ethyl-6-methylphenyl)- |
DIVK1C_006722 |
SPECTRUM_001979 |
NCGC00090754-01 |
harness |
acetochlor [ansi:bsi:iso] |
acenit |
epa pesticide chemical code 121601 |
einecs 251-899-3 |
azetochlor |
caswell no. 003b |
acetochlore [iso-french] |
erunit |
mg 02 |
nevirex |
mon 097 |
ccris 7709 |
o-acetotoluidide, 2-chloro-n-(ethoxymethyl)-6'-ethyl- |
hsdb 6550 |
brn 2859702 |
34256-82-1 |
acetochlor |
SPECTRUM5_002071 |
NCGC00090754-02 |
NCGC00090754-03 |
KBIO1_001666 |
KBIO2_002536 |
KBIO3_002045 |
KBIOSS_002545 |
KBIO2_005104 |
KBIO2_007672 |
KBIOGR_001265 |
SPBIO_001910 |
SPECTRUM3_000873 |
SPECTRUM4_000713 |
SPECTRUM2_001915 |
SPECPLUS_000626 |
SPECTRUM330089 |
BSPBIO_002545 |
NCGC00090754-04 |
NCGC00090754-05 |
MLS001055474 |
smr000777859 |
SR-01000846094-2 |
sr-01000846094 |
MLS002695926 |
FT-0661052 |
NCGC00090754-07 |
NCGC00090754-09 |
NCGC00090754-06 |
NCGC00090754-08 |
HMS3029L16 |
cas-34256-82-1 |
NCGC00254793-01 |
dtxcid303848 |
NCGC00259994-01 |
dtxsid8023848 , |
tox21_300889 |
tox21_202445 |
CHEMBL1517425 |
A822138 |
CCG-39458 |
8l08wmo94k , |
unii-8l08wmo94k |
AKOS015889911 |
acetochlor [iso] |
2-chloro-n-ethoxymethyl-6'-ethylacet-o-toluidide |
acetochlor [mi] |
acetochlor [hsdb] |
SCHEMBL21390 |
2-chloro-n-(ethoxymethyl)-n-(2-ethyl-6-methylphenyl)acetamide # |
2-chloro-2'-ethyl-6'-methyl-n-(ethoxymethyl) acetanilide |
2-chloro-2'-ethyl-6'-methyl-n-(ethoxymethyl)acetanilide |
acetochlor d11 |
GS-6265 |
acetochlor, pestanal(r), analytical standard |
EN300-140829 |
acetochlor 100 microg/ml in cyclohexane |
n-(ethoxymethyl)-2-chloro-n-(2-ethyl,6-methylphenyl)acetamide |
J-019525 |
Q419732 |
acetochlor 100 microg/ml in acetonitrile |
H10515 |
A935755 |
2-chloro-n-((ethoxy-d5)methyl-d2)-n-(2-ethyl-6-(methyl-d3)phenyl-5-d)acetamide |
2-chloro-n-ethoxymethyl-n-(2'-ethyl-6'-methylphenyl) acetamide |
Z1705874565 |
Acetochlor (ACT) is a chloroacetamide herbicide applied to various crops worldwide. It is one of the top selling herbicides on the global market. The neurotoxic effects of its chiral isomers on humans and environmental organisms remain uncertain.
Excerpt | Reference | Relevance |
---|---|---|
"Acetochlor (ACT) has been frequently detected in the aquatic environment and implicated in disruption of the immune system in fish, the mechanisms of which, especially at enantiomeric levels, remains unclear. " | ( Stereoselective induction of developmental toxicity and immunotoxicity by acetochlor in the early life stage of zebrafish. Deng, M; Jin, Y; Lin, C; Liu, W; Lu, B; Tu, W; Wu, Y; Xu, C; Zhang, C, 2016) | 2.11 |
The study was to explore the toxic effect and the possible mechanism of toxic action of acetochlor using zebrafish larvae. Noncancerous adverse effects observed at the lowest dose for chloroacetanilide herbicides. Estrogen receptor positive (ER+) MCF-7 human mammary carcinoma, HepG2 human hepatocellular carcinoma were found.
Excerpt | Reference | Relevance |
---|---|---|
" The result showed that one of three test chemicals had its toxicity on the earthworm population, and the single toxic sequence of the chemicals was acetochlor > methamidophos > Cu." | ( [Single and binary-combined toxicity of methamidophos, acetochlor and Cu on earthworm Eisenia foetida]. Liang, J; Zhou, Q, 2003) | 0.77 |
" Estrogen receptor positive (ER+) MCF-7 human mammary carcinoma, HepG2 (ER+) human hepatocellular carcinoma and VERO estrogen receptor negative (ER-) non-transformed monkey fibroblast cell lines were treated with alachlor and acetochlor (2-500 microg/ml) as toxic agents, and RESV (10 microM) as preventive agent." | ( Chemopreventive properties of trans-resveratrol against the cytotoxicity of chloroacetanilide herbicides in vitro. Jakab, MG; Kocsis, Z; Marcsek, ZL; Szende, B; Tompa, A, 2005) | 0.51 |
"To assess the toxic effects of the herbicide acetochlor on earthworms, we exposed Eisenia fetida (Savigny) to artificial soils (OECD soil) supplemented with different concentrations (5, 10, 20, 40 and 80 mg kg-1 soil) of acetochlor." | ( The fate of herbicide acetochlor and its toxicity to Eisenia fetida under laboratory conditions. Ge, F; Jing, B; Liu, X; Xiao, N, 2006) | 0.91 |
" The single toxic effect test showed that the two agrochemicals had their toxicity to the earthworms living in phaiozem." | ( Toxic effects of acetochlor and methamidophos on earthworm Eisenia fetida in phaiozem, northeast China. Ji-dong, L; Qi-xing, Z; Qian-ru, Z, 2006) | 0.67 |
" Acetochlor and its photolytic degradation products were found to be more toxic to bacteria than fungi." | ( Microbial toxicity of pesticide derivatives produced with UV-photodegradation. Kiss, A; Naár, Z; Virág, D, 2007) | 1.25 |
" Toxic effects of acetochlor and methamidophos combination on nifH gene were also apparent." | ( Toxic effects of acetochlor, methamidophos and their combination on nifH gene in soil. Li, XY; Su, ZC; Zhang, CG; Zhang, HW; Zhang, Q, 2007) | 1.01 |
"Noncancerous adverse effects observed at the lowest dose for chloroacetanilide herbicides alachlor [2-chloro-2',6'-diethyl-N-(methoxymethyl)-acetanilide] and acetochlor [2-chloro-2'-methyl-6'-ethyl-N-(ethoxymethyl)acetanilide], but not metolachlor [2-chloro-2'-ethyl-6'-methyl-N-(1-methyl-2-methoxymethyl)acetanilide], are hepatotoxicity in rats and dogs." | ( Comparative cytotoxicity of alachlor, acetochlor, and metolachlor herbicides in isolated rat and cryopreserved human hepatocytes. Kale, VM; Meyer, SA; Miranda, SR; Wilbanks, MS, 2008) | 0.81 |
"The aim of this work is the Toxicity Identification Evaluation (TIE) of highly toxic tank truck cleaning wastewater effluent." | ( Wastewater treatment plant modeling supported toxicity identification and evaluation of a tank truck cleaning effluent. Blust, R; De Schepper, W; Dries, J; Geuens, L, 2010) | 0.36 |
" This study was to explore the toxic effect and the possible mechanism of toxic action of acetochlor using zebrafish larvae whose toxicity profiles have been confirmed to be strikingly similar with mammalian." | ( In vivo cardiovascular toxicity induced by acetochlor in zebrafish larvae. Chen, L; Chu, T; Gui, W; Liu, H; Zhu, G, 2017) | 0.94 |
Pb forms in clean and polluted phaiozems of northeast China. Response of Pb bioavailability to acetochlor application.
Excerpt | Reference | Relevance |
---|---|---|
" Bioavailability was determined by radioactivity disposition in blood, urine and faeces." | ( In vivo percutaneous absorption of acetochlor in the rhesus monkey: dose-response and exposure risk assessment. Maibach, HI; Melendres, JL; Wester, RC, 1996) | 0.57 |
"By using Pb-fractionation analytical methods and Pb-acetochlor response experiments, it was studied the Pb forms in clean and polluted phaiozems of northeast China and the response of Pb bioavailability to acetochlor application." | ( [Influence of acetochlor on Pb forms and their bioavailability in phaiozem of northeast China]. Guo, G; Sun, F; Sun, T; Zhou, Q, 2004) | 0.93 |
"Biochar (BC) can alter the fate and bioavailability of pesticides in soil." | ( Effects of biochars on the fate of acetochlor in soil and on its uptake in maize seedling. Dong, F; Li, Y; Liu, X; Pan, X; Wu, X; Xu, J; Zheng, Y, 2018) | 0.76 |
" To assess environmental behaviors and minimal dosage of acetochlor application in the realistic soil, we systematically investigated the acetochlor adsorption/desorption, mobility, leaching, degradation, weed bioavailability and lethal dosage of acetochlor in three soil types including Nanjing (NJ), Yancheng (YC) and Yingtan (YT)." | ( Environmental disappearance of acetochlor and its bioavailability to weed: A general prototype for reduced herbicide application instruction. Guo, QN; Xie, F; Yang, H; Zhang, N, 2021) | 1.15 |
The sulfoxide was found to be the major plasma metabolite in rats dosed with acetochlor. The contents of CHL and SP could be considered as biomarkers of stress by acetichlor in soil. There are dose-response relationships between the SP content in leaves and the concentration of acetchlor in soils.
Excerpt | Relevance | Reference |
---|---|---|
" The dosing area was not covered." | ( In vivo percutaneous absorption of acetochlor in the rhesus monkey: dose-response and exposure risk assessment. Maibach, HI; Melendres, JL; Wester, RC, 1996) | 0.57 |
" The sulfoxide was found to be the major plasma metabolite in rats dosed with acetochlor." | ( Acetochlor-induced rat nasal tumors: further studies on the mode of action and relevance to humans. Ashby, J; Clapp, MJ; Green, T; Lee, R; Lund, VJ; Moore, RB; Willis, GA, 2000) | 1.98 |
" But the contents of CHL and SP could be considered as biomarkers of stress by acetochlor in soil and there are dose-response relationships between the SP content in leaves and the concentration of acetochlor in soil." | ( [Effects of herbicide acetochlor on physiological mechanisms in wheat and biomarkers identification]. Chao, L; Chen, S; Cui, S; Zhou, QX, 2007) | 0.88 |
" A second group of adult ovariectomized female rats was dosed for 6 days with ACT (153." | ( Neonatal exposure to herbicide acetochlor alters pubertal development in female wistar rats. Rollerova, E; Urbancikova, M; Wsolova, L, 2011) | 0.66 |
" To assess environmental behaviors and minimal dosage of acetochlor application in the realistic soil, we systematically investigated the acetochlor adsorption/desorption, mobility, leaching, degradation, weed bioavailability and lethal dosage of acetochlor in three soil types including Nanjing (NJ), Yancheng (YC) and Yingtan (YT)." | ( Environmental disappearance of acetochlor and its bioavailability to weed: A general prototype for reduced herbicide application instruction. Guo, QN; Xie, F; Yang, H; Zhang, N, 2021) | 1.15 |
Role | Description |
---|---|
herbicide | A substance used to destroy plant pests. |
xenobiotic | A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means. |
environmental contaminant | Any minor or unwanted substance introduced into the environment that can have undesired effects. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
monocarboxylic acid amide | A carboxamide derived from a monocarboxylic acid. |
organochlorine compound | An organochlorine compound is a compound containing at least one carbon-chlorine bond. |
aromatic amide | An amide in which the amide linkage is bonded directly to an aromatic system. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 28.1838 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
acetylcholinesterase | Homo sapiens (human) | Potency | 33.6101 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395 |
Nrf2 | Homo sapiens (human) | Potency | 25.1189 | 0.0920 | 8.2222 | 23.1093 | AID624171 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 13.0392 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 39.2624 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
SMAD family member 2 | Homo sapiens (human) | Potency | 46.7004 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 21.8438 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
SMAD family member 3 | Homo sapiens (human) | Potency | 46.7004 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
TDP1 protein | Homo sapiens (human) | Potency | 26.9836 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 19.1241 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 33.6948 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID1259381; AID588516; AID743035; AID743042; AID743054; AID743063 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 44.6684 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 31.6228 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 40.8006 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 12.0160 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 17.2918 | 0.0004 | 17.9460 | 75.1148 | AID1346784; AID1346795 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 25.6404 | 0.0002 | 14.3764 | 60.0339 | AID588533; AID720692 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 58.9131 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 25.0291 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531; AID588544; AID588546 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 22.6704 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 45.7889 | 0.3758 | 27.4851 | 61.6524 | AID588527; AID743217; AID743220 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 4.1086 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982; AID720659 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 32.3062 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID588513; AID588514; AID743069; AID743075; AID743078; AID743080 |
peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 28.6592 | 0.0010 | 24.5048 | 61.6448 | AID588534; AID588535; AID743215 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 22.0284 | 0.0010 | 19.4141 | 70.9645 | AID588536; AID588537; AID743191 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 29.3808 | 0.0237 | 23.2282 | 63.5986 | AID588541; AID743222; AID743223; AID743241 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 41.7075 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 8.1542 | 0.0016 | 28.0151 | 77.1139 | AID1224843 |
activating transcription factor 6 | Homo sapiens (human) | Potency | 26.9993 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 123.2935 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 31.6228 | 0.3162 | 12.4435 | 31.6228 | AID902 |
thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 50.1187 | 0.0100 | 39.5371 | 1,122.0200 | AID588547 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 0.0580 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 62.3414 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 60.5113 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 15.9310 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636; AID743202; AID743219 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
geminin | Homo sapiens (human) | Potency | 9.0476 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 15.8489 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 47.2062 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 72.6747 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 47.2062 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 28.9323 | 0.0119 | 17.9420 | 71.5630 | AID651632 |
Ataxin-2 | Homo sapiens (human) | Potency | 28.9323 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
AID1100793 | Binding affinity to SafBP receptor in Zea mays (maize) seedlings by [3H]Saf(R-29148) binding assay | 2000 | Journal of agricultural and food chemistry, Mar, Volume: 48, Issue:3 | Comparative three-dimensional quantitative structure-activity relationship study of safeners and herbicides. |
AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (0.84) | 18.7374 |
1990's | 17 (7.14) | 18.2507 |
2000's | 97 (40.76) | 29.6817 |
2010's | 77 (32.35) | 24.3611 |
2020's | 45 (18.91) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (45.95) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 3 (1.21%) | 6.00% |
Case Studies | 1 (0.40%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 243 (98.38%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |